Abbott Nutrition Sales Weakened By China Recall
This article was originally published in The Tan Sheet
Abbott Nutrition has “invested considerably” in marketing to restore its reputation with consumers after its third-quarter infant formula sales were slowed by a recall in China.
You may also be interested in...
The infant nutritionals firm has put a poorly timed price increase behind it and is optimistic about the effects of a Hong Kong limit on formula exports on China sales. Additionally, a recall of Danone baby nutrition products in Asia is expected to benefit Mead Johnson over the next 9 to 12 months.
In Brief: NAD trims BPI claims, formula price-fixing in China, FDA warns Formulife and identifies spiked supplements, NBTY’s consumer redress
BPI discontinues claims at NAD’s behest; China levies fines for infant formula price-fixing; Public Citizen pans OTC Oxytrol; FDA advises ProNatural supplements cannot be topical; FDA warns Formulife on DMAA; FDA uncovers more spiked supplements; NBTY pays back consumers over omega-3 claims; Algean reminded about re-inspection fee.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.